Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.
Peripheral T Cell Lymphoma
BIOLOGICAL: lacutamab
Occurrence of adverse events (AEs), Frequency and intensity of adverse events and serious adverse events., From consent is obtained until EOT visit (28 days after the last administration of study drug lacutamab)
This is an open-label, single-arm multicenter study. Eligible patients will be enrolled and will receive fixed dose of 750mg Lacutamab as a 1-hour IV infusion.